ClinicalTrials.gg

TargetBeta

ENTPD1

ectonucleoside triphosphate diphosphohydrolase 1 · also ATP-DPH, NTPDase-1, ATPDase, SPG64 · CD molecules

3 programs in company-led studies act on ENTPD1, from 3 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Anti-CD39 Antibody/TGF-beta RII Ectodomain Fusion Protein ES014ruleElpiscience (Suzhou) Biopharmaphase 232 running–NCIt
Anti-CD39 Monoclonal Antibody IPH5201Innate Pharmaphase 221 running–a judged reading
Anti-PD-1/Anti-CD39 Bispecific Antibody BNT317ruleBioNTechphase 211 runningPDCD1NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.